Bio-Path Holdings to Present Clinical Data at the 63rd Annual American Society of Hematology Annual Meeting

Rhea-AI Summary

Bio-Path Holdings (BPTH) announced a poster presentation at the 2021 American Society of Hematology (ASH) Annual Meeting from December 11-14, 2021. The presentation will feature safety and preliminary efficacy data from the Phase 2 trial of prexigebersen (BP1001), targeting acute myeloid leukemia. Dr. Maro Ohanian from M.D. Anderson Cancer Center will lead the presentation on December 11, detailing the therapy's safety and efficacy in patients with high-risk and relapsed/refractory AML. This event is pivotal for showcasing BPTH's innovative drug development.

Positive

• Upcoming presentation at ASH Annual Meeting highlights the importance of BP1001 in cancer treatment.
• Phase 2 trial shows promising safety and preliminary efficacy data for BP1001 against acute myeloid leukemia.

Negative

• None.

HOUSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize^® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced an upcoming poster presentation at the 2021 American Society of Hematology (ASH) Annual Meeting and Exposition, taking place from December 11-14, 2021 in Atlanta, GA. In addition, ASH abstracts will appear in the November supplemental issue of Blood.

Dr. Maro Ohanian, Associate Professor of the Department of Leukemia at The University of Texas M.D. Anderson Cancer Center, will present the safety and preliminary efficacy data from the ongoing Phase 2 trial of prexigebersen (BP1001), the Company’s lead drug candidate, for the treatment of acute myeloid leukemia.  

Details for the presentation are as follows:
Date: Saturday, December 11, 2021
Presentation Time: 5:30 PM - 7:30 PM Eastern Time
Location: Georgia World Congress Center, Hall B5
Session Name: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I
Title: Safety and Efficacy of Lower Intensity Induction Therapy with Intravenous Prexigebersen (BP1001) in Patients with High-Risk and Relapsed/Refractory Acute Myeloid Leukemia (AML)

About Bio-Path Holdings, Inc.

Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers and in preclinical studies for solid tumors. This is followed by BP1002, targeting the Bcl-2 protein, which is being evaluated in lymphoma clinical studies.

For more information, please visit the Company's website at http://www.biopathholdings.com.

Contact Information:

Investors

Will O’Connor
Stern Investor Relations, Inc.
212-362-1200
will@sternir.com   

Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369

FAQ

What is the purpose of the Phase 2 trial for prexigebersen (BP1001)?

The Phase 2 trial for BP1001 aims to evaluate its safety and preliminary efficacy in treating acute myeloid leukemia.

When will Bio-Path Holdings present their findings at the ASH Annual Meeting?

Bio-Path Holdings will present findings on December 11, 2021, from 5:30 PM to 7:30 PM Eastern Time.

Where is the ASH Annual Meeting taking place?

The ASH Annual Meeting is being held at the Georgia World Congress Center in Atlanta, GA.

What are the next steps for BPTH after the ASH presentation?

Following the ASH presentation, BPTH may proceed to further trials or data analysis to solidify the findings from the Phase 2 trial.

What is prexigebersen (BP1001) targeting in its treatment approach?

Prexigebersen (BP1001) targets the Grb2 protein, which is relevant in the treatment of blood cancers.